Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: Biologics

TNF Inhibitor Tied to Lower Cardiovascular Risk in Psoriasis

Lorraine L. Janeczko  |  

NEW YORK (Reuters Health)—Psoriasis patients treated with tumor necrosis factor-alpha (TNF) inhibitors may have a lower risk of major cardiovascular (CV) events than those treated with methotrexate (MTX), according to a new study. “The findings do not surprise me. TNF inhibitors control inflammation better than methotrexate,” lead author Dr. Jashin J. Wu of Kaiser Permanente…

Myocardial Inflammation Elevated in Active RA, Eases with DMARD Therapy

Megan Brooks  |  

NEW YORK (Reuters Health)—Patients with active rheumatoid arthritis (RA) and no known heart disease may have subclinical myocardial inflammation, which improves with disease-modifying therapy, new research shows. “We know that patients with RA have higher risk of cardiovascular events, including heart failure and we really don’t know why. Maybe myocardial inflammation is one of the…

2015 Treatment Recommendation Updates for Psoriatic Arthritis Address Comorbidities, New Medications

  |  

In May, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published its recommendations for the treatment of psoriatic arthritis (PsA).1 The updated recommendations represent advances in drug development and availability since previous recommendations published in 2009, as well changes in treatment paradigms and the importance of associated aspects of the disease.2…

Update on Legislation, Notification Rules Concerning the Substitution of Interchangeable Biologic Drugs

  |  

Although the FDA has not yet awarded the title of interchangeable to any biosimilar, legislation that governs their substitution will continue to be a dominant state issue in 2017. Since 2013, 24 states and Puerto Rico have passed legislation regarding interchangeable biologics. As many as 15 states will have biosimilar-related legislation introduced by coalitions in…

ACR President Dr. Joan Von Feldt Reflects on Her Year in Office, Advancing Rheumatology!

Joan M. Von Feldt, MD, MSEd, FACR, FACP  |  

This has been a year of tremendous growth, change and achievement for the ACR, and I have been fortunate to lead the ACR in these endeavors. The ACR and ARHP, including the ACR Executive Committee, the ACR Board of Directors, standing and special committee chairs and hundreds of dedicated volunteers, have contributed to this growth…

Metabolomic Profiles: A Biomarker for the Biological Treatment of RA

  |  

A recent study suggests that metabolites may be a biomarker for disease activity in patients with rheumatoid arthritis (RA). For the first time, researchers identified serum metabolomic profiles and 16 clinical parameters that serve as a reasonably predictive model for a patient’s therapeutic response to biological treatment of RA, specifically TNF-α inhibitor therapy…

Treating the Athlete: New Thoughts on How to Prevent & Treat Arthritis in Athletes & Raise Their Awareness

  |  

All athletes—amateur and professional—should understand their risks for developing injury-related arthritis. Rheumatologists and other physicians at the Hospital for Special Surgery in New York take a rapid approach to treating athletes, often considering intense physical therapy, innovative treatments and surgery much sooner than for the average patient—all to keep joints healthy and enable athletes to play for as long as possible…

Challenges Rheumatologists Will Face in 2017

  |  

Rheumatologists and rheumatology health professionals interested in knowing more about the major legislative and regulatory issues that may have an impact on their practice will want to attend the Legislative and Regulatory Update 2016 session at the upcoming ACR/ARHP Annual Meeting. On Tuesday, Nov. 15, from 7:30–8:30 a.m. in Room 140A, Will Harvey, MD, MSc,…